Whilst these studies highlighted KRAS mutations as contraindication for TRAIL-R agonistic treatments, the function and reasons for high endogenous expression of TRAIL and TRAIL-Rs observed in these cancers remained unknown. This evidence concerns the gene TNFSF10 and cancer.